drugset / Trial / NCT03025477
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
Phase 2
Recruiting
84 enrolled
Groupe Hospitalier Diaconesses Croix Saint-Simon
GERCOR - Multidisciplinary Oncology Cooperative Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Timeline
- Start
- 2016-10
- Primary completion
- 2021-10
- Completion
- 2032-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intrathecal |
| Subject | Epirubicin | Small molecule | 60 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |